Editorial Board ::: Drug Metabolism Letters

ISSN: 1874-0758 (Online)
ISSN: 1872-3128 (Print)


Volume 11, 4 Issues, 2017


Download PDF Flyer




Drug Metabolism Letters

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Zhiyang Zhao
Alliance Pharma
Malvern, PA
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Zhiyang Zhao (Biography
Zhiyang Zhao

Zhiyang Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Tech, Blacksburg, Virginia, USA. Dr. Zhao’s biopharmaceutical/pharmaceutical work experience encompasses over 25 years of research in metabolic and pharmacokinetic properties of compounds for drug discovery and development at Pfizer, GlaxoSmithKline and Amgen. Currently, Dr. Zhao serve as Chief Scientific Officer (CSO) at Alliance Pharma, Inc. and appointed as an adjunct professor at the School of Pharmacy, the University of North Carolina at Chapel Hill. Dr. Zhao has published over 50 peer reviewed original research papers and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.

)

Alliance Pharma
Malvern, PA
USA



Co-Editor:

Suresh K Balani
Takeda Pharmaceuticals International Company
Cambridge, MA
USA


Associate Editors:

Region: USA
Michael Sinz (Biography
Michael Sinz

Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.

)

Bristol Myers Squibb
Wallingford, CT
USA

Shufeng Zhou
University of South Florida
Florida, FL
USA

Region: Asia
Ken-ichi Fujita (Biography
Ken-ichi Fujita

Dr. Fujita obtained a Ph.D. from the Graduate School of Pharmaceutical Sciences, Hokkaido University (Sapporo, Japan). Dr. Fujita also holds a Bachelor of Engineering from the School of Engineering, Tohoku University (Sendai, Japan). Currently Dr. Fujita is a Professor in the Institute of Molecular Oncology, Showa University. His present research field is clinical pharmacology in cancer pharmacotherapy. He has published more than 100 scientific publications. Dr. Fujita is currently the Associate Editor of this journal (Current Drug Metabolism).

)

Showa University
Tokyo
Japan

Lee Jia (Biography
Lee Jia

Lee Jia is currently Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talents plan), and the founder Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China, managing 10 cancer metastasis detection and prevention-related projects. Prior to this position, he was the Senior Project Officer with the Developmental Therapeutics Program at the National Cancer Institute, NIH, USA (2002-2012). Before joining the NCI/NIH in 2002, he was Associate Director of Cancer Therapy and Research Center in San Antonio, TX, where he was responsible for translational research, and Associate Member of San Antonio Cancer Institute. He received his Ph.D. degree in Pharmacology from the State University of New York under the supervision of Distinguished Professor, Dr. Robert Furchgott, the 1998 Nobel Laureate. Dr. Jia has contributed >150 original papers to high-impact journals, including Science, Nature, PNAS, Nano Today, Blood. He serves as Associate Editor of CDM and CDL. He is the Fellow of the American Association of Pharmaceutical Scientists (AAPS) and held leadership position with AAPS.

)

Fuzhou University
Fujian
China

Region: Europe
Nico P.E. Vermeulen (Biography
Nico P.E. Vermeulen

Prof. Nico P.E. Vermeulen received a doctorate degree in Chemistry (1975, University of Nijmegen, NL) and a PhD degree in Pharmacology (1980, University of Leiden, NL). He was appointed full professor in Molecular Toxicology at VU University Amsterdam (1985). Currently, he is also Director of AIMMS (Amsterdam Institute for Molecules, Medicines and Systems, at VU University). He is author of > 405 peer reviewed publications and was listed at the ISI HighlyScited.com list (e.g. 2001 and 2014). He is interested in the roles molecular and computational toxicology and drug metabolism can play in drug discovery, development and safety assessment.

)

Vrije Universiteit Amsterdam
Amsterdam
The Netherlands


Editorial Board Members:

U.A. Argikar (Biography
U.A. Argikar

Upendra A. Argikar is a Senior Research Investigator at Novartis Institutes for Biomedical Research, Inc. in Cambridge, Massachusetts, USA. He received a Ph.D. in Medicinal Chemistry from University of Minnesota, USA. He has 15+ years of research experience in drug metabolism and pharmacokinetics. At Novartis he has been an active member of projects spanning many disease areas. Currently, he focuses on metabolite identification and structure elucidation of new chemical entities and clinical candidates. Upendra has continued to be interested in conjugative metabolism by uridine diphospho-glucuronosyl transferases, a topic on which he has co-authored research articles, reviews, and book chapters.

)

Novartis Institutes for BioMedical Research, Inc.
Cambridge, MA
USA

A. Collier (Biography
A. Collier

Dr. Collier's sub-specialty is drug metabolism and pharmacokinetics, primarily the phase II (conjugation) enzymes, with a strong focus on pregnancy and pediatrics. A winner of the 2011 SimCYP Consortium Award for Most Informative Report ("in recognition of scientific research that is leading the field in ADME, IVIVE, pharmacokinetics, modeling and simulation"), Dr. Collier uses a combination of wet laboratory work and in silico modeling to provide greater understanding of developmental pharmacology and improve drug/chemical safety. Along with her collaborators, she also performs research and publishes regularly in the fields of human and environmental toxicology and endocrinology.

)

University of British Columbia
Vancouver
Canada

H. Glatt
German Institute of Human Nutrition (DIfE)
Nuthetal
Germany

E. Kantharaj
R & D Technical, D3, A*STAR
Singapore

T. Kàroly
Preclinical Imaging Center
Budapest
Hungary

S. Mandlekar (Biography
S. Mandlekar

Sandhya Mandlekar is the Director of Pharmaceutical Candidate Optimization Department at the Biocon Bristol-Myers Squibb R&D Center (BBRC) in Bangalore, India. She also worked in the non-clinical DMPK field at BMS, NJ and DuPont Pharmaceuticals, DE for several years. She received her Ph.D. degree in Pharmaceutical Sciences from the College of Pharmacy at the University of Illinois, Chicago. Sandhya was responsible for setting up and equipping the laboratories, recruitment and staffing, and directing a group of scientists in drug metabolism, pharmacokinetics, bioanalytical sciences, and toxicology at the BBRC. She has published over 50 peer-reviewed articles and also serves as a reviewer for reputed journals.

)

Bristol-Myers Squibb India Pvt. Ltd.
Bangalore
India

C. O. Onyeji (Biography
C. O. Onyeji

Promoted to Professorship position in 1999 at Obafemi Awolowo University, Ile- Ife, Nigeria, Prof Cyprian Onyeji occupied various posts including Deanship of his Faculty. Outside the University, he served as Governing Board member of different establishments. He was appointed Vice-Chancellor of Enugu State University of Science and Technology, and completed the tenure in 2015. He has made excellent contributions to the advancement of Science through his studies with focus on pharmacokinetic, metabolism and pharmacodynamic evaluations of anti-infective drugs, with the overall objective of generating information relevant for optimization of therapeutic utility of the drugs.

)

Obafemi Awolowo University
Ile-Ife
Nigeria

S. Pusalkar (Biography
S. Pusalkar

Dr. Pusalkar obtained a doctorate degree (Ph.D.) in Medicinal Chemistry from Massachusetts College of Pharmacy and Health Sciences, Boston, MA. Dr. Pusalkar has more than 15 years of experience in drug metabolism and pharmacokinetics field and currently leads the Enzymology Group at Takeda Pharmaceuticals, Intl’ Co. in Cambridge, MA.

)

Takeda Pharmaceuticals Inc.
Cambridge, MA
USA

M. Soars (Biography
M. Soars

Dr Soars is a Senior Principal Scientist in the Metabolism and Pharmacokinetics department at Bristol-Myers Squibb in Wallingford CT. He received his Bachelors in biochemistry from the University of Warwick in 1998 and a Phd from the University of Dundee in 2002. From 2002-2003, he completed a postdoctoral fellowship at Eli Lilly where he worked on drug glucuronidation under the supervision of Steve Wrighton. He then moved to AstraZeneca where he worked for 8 years developing and implementing both drug metabolism assays and more recently transporter methodology. Since 2011 Dr. Soars has worked at Bristol –Myers Squibb where he helped develop the transporter strategy in Drug Discovery. Research interests include the prediction of pharmacokinetics and drug-drug interactions for new chemical entities and also the application of drug transporter methodology in early Drug Discovery. Dr Soars has published more than 30 scientific publications and is on the Editorial advisory board for a number of publications including Xenobiotica, Current Drug Metabolism and Drug Metabolism letters.

)

Bristol-Myers Squibb
Wallingford, CT
USA

B. Wen (Biography
B. Wen

Bo Wen, Ph.D. is Research Fellow at GlaxoSmithKline Pharmaceutical Research and Development. Prior to GSK, Dr. Wen held multiple positions at Hoffmann-La Roche and Bristol- Myers Squibb. He received his B.Sc. in Pharmaceutical Sciences from China Pharmaceutical University and Ph.D. in Medicinal Chemistry from the University of Washington. He has authored over 30 peer-reviewed papers and book chapters in the fields of biotransformation, bioactivation of xenobiotics, and the molecular mechanisms of drug metabolism and chemical toxicology.

)

GlaxoSmithKline
King of Prussia, PA
USA

A.M. Yu (Biography
A.M. Yu

Dr. Aiming Yu is a Professor in the Department of Biochemistry & Molecular Medicine and a member of the Comprehensive Cancer Center at UC Davis School of Medicine. He also directs the PK/PD Bioanalytical Core Facility in support of drug development programs at UC Davis. Prof. Yu’s research interests include microRNA pharmacoepigenetics, and cancer pharmacology and therapy. His current research focuses on the delineation of mechanistic functions of noncoding RNAs in the control of cellular processes including drug disposition and tumor progression, and development of novel noncoding RNA-based therapeutics.

)

University of California-Davis
Sacramento, CA
USA

G.D. Bowers
GlaxoSmithKline
Research Triangle Park, NC
USA

J.S. Daniels
Vanderbilt University Medical Center
Nashville, TN
USA

W.G. Humphreys
Bristol-Myers Squibb
Princeton, NJ
USA

R.S. King (Biography
R.S. King

Dr. King earned a doctorate (Ph.D.) in Medicinal Chemistry from the University of Iowa, Iowa City. Her postdoctoral fellowship was in molecular toxicology at the National Center for Toxicological Research, followed immediately by earning a faculty position at the University of Rhode Island, College of Pharmacy in 1999. Dr. King is currently Professor of Biomedical and Pharmaceutical Sciences. Dr. King's research spans protein structural biology, receptor-based drug design, all aspects of drug-xenobiotic-hormone metabolism, and liver enzymology.

)

University of Rhode Island
Kingston, RI
USA

A.P. Li (Biography
A.P. Li

Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.

)

In Vitro ADMET Laboratories
Columbia, MD
United States

M. Moghaddam (Biography
M. Moghaddam

Dr. Mehran F. Moghaddam obtained his PhD in medicinal chemistry at Oregon State University-School of Pharmacy and investigated novel lipid metabolism at University of California-Davis as a postdoctoral researcher. He also completed an executive MBA at University of Southern California. He started his industrial career by joining DuPont in 1995. Subsequently, he worked in Pfizer and Celgene. He is currently the head of Discovery Drug Metabolism and Pharmacokinetics (DMPK) at Celgene, a global biopharmaceutical company with marketed blockbuster drugs in oncology and anti-inflammatory spaces.

Dr. Moghaddam has been a co-inventor on more than 5 patents. He has authored/co-authored more than 50 manuscripts on a variety of subject matters. He is on the editorial board of Drug Metabolism Letters and DARU. Additionally, he is a section editor for Current Medicinal Chemistry.

)

Celgene Corporation
San Diego, CA
USA

K.B. Park (Biography
K.B. Park

Professor Kevin Park is currently Professor of Pharmacology and Head of the Institute of Translational Medicine at the University of Liverpool. Professor Park is a Fellow of the Royal College of Physicians, a Fellow of the Academy of Medical Sciences and also a Commissioner on Human Medicines. The over-riding theme of his work is bringing “molecule–to-man” and back again, to enable the prediction of adverse drug reactions based on the chemical structure of the drug and the identification of susceptible individuals. This work has been expanded by using pharmacogenomics and toxicogenomics to link findings in patients to the chemical structure of the drug. The group are now in a position to provide solutions to adverse drug reactions through research in two areas: 1) improved drug design and 2) the delivery of individualised medicines.

)

University of Liverpool
Liverpool
UK

M.S. Roberts
University of South Australia
Adelaide
Australia

M. Ulgen (Biography
M. Ulgen

Prof. Dr. Mert Ulgen graduated from Marmara University, Faculty of Pharmacy, Istanbul, Turkey in 1981. He finished his MSc degree at the same department and in 1992, he obtained a PhD degree from University of London, King's College, Biopharmacy Department in the area of Drug Metabolism. He returned to Turkey and became an associated Professor in 1993 and a full professor in 1999 at the same department in the area of Pharmaceutical Chemistry. He has got a number of papers on drug synthesis and in vitro hepatic microsomal metabolism of xenobiotics. He directed a number of MSc and PhD thesis. He retired from Marmara University in June 2009 and he became a full time Professor at Acıbadem University, Vocational School of Health Services in the same year. He has a number of administrative duties. He is also a full time chemistry lecturer. He was Director of Enstitute of Health Sciences in Acıbadem University one term (2013-2016). He established Faculty of Pharmacy at the same University in early 2016 and he is currently dean of Pharmacy. He is also head of "Management in Drug Industry" MSc Program.

)

Acibadem University
Istanbul
Turkey

W. Xie
University of Pittsburgh School of Pharmacy
Pittsburgh, PA
USA

D. Capone
Federico II University
Naples
Italy

R. Dickinson
University of Queensland at Royal Brisbane Hosp.
Queensland
Australia

M. Kajbaf (Biography
M. Kajbaf

Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy Department in the area of drug metabolism and MSc from Aston University, Birmingham. Currently Dr Kajbaf is Senior Scientist at Aptuit. He has received several awards and honors, such as: Aptuit CEO Excellence Award, GlaxoSmithKline the psychiatry CEDD Leadership Team Award. He is also on the editorial board for several journals. He has published over 33 research articles related to drug metabolism, in vivo-in vitro correlation, drug-drug interaction, HPLC, NMR and mass spectrometry.

)

GlaxoSmithKline S.p.A.
Fleming, Verona
Italy

G.N. Kumar (Biography
G.N. Kumar

Gondi N. Kumar obtained B. Pharm from Kakatiya University, India, M. Pharm from Andhra University, India, Ph.D. from University of Florida, Gainesville, FL, and post-doctoral fellowship evaluating metabolism of paclitaxel at the Medical University of South Carolina. He is a diplomate of American Board of Toxicology. Prior to Celgene, he had productive careers at Abbott and Amgen, as principal DMPK investigator for lopinavir/ritonavir (KaletraTM), cinacalcet (SensiparTM) and abarelix (PlenaxisTM). He has published over 50 research papers, PhRMA perspectives and book chapters, and is a co-inventor on multiple patents.

)

Celgene Corporation
Summit, NJ
USA

B.L. Lum (Biography
B.L. Lum

Dr. Lum is a Principal Scientist at Genentech, Inc., where he has been employed for approximately 13 years in the Department of Clinical Pharmacology. He has served a leading role in the development and marketing approvals for a variety of small molecule and protein therapeutics, such as trastuzumab (Herceptin IV/SC), erlotinib (Tarceva), bevacizumab (Avastin), pertuzumab (Perjeta) vismodegib (Erivedge), and ado-trastuzumab (Kadcyla). Prior to moving to Genentech, Dr. Lum was a tenured Professor of Pharmacy at the University of the Pacific and Associate Director of the Clinical Trials Office in the Stanford University Medical Center. He has published over 100 manuscripts.

)

Genentech Research and Early Development
South San Francisco, CA
USA

A.F. Nassar
Brandies University
Waltham, MA
USA

C. Prakash
CP Pharma Consulting Principal, Drug Metabolism and Pharmacokinetics
MA
USA

J.F. Rusling (Biography
J.F. Rusling

James F. Rusling was awarded the B.Sc. in Chemistry from Drexel University in 1969, and Ph. D. from Clarkson University in 1979. He is Professor of Chemistry at University of Connecticut, Professor of Surgery and member of the Neag Cancer Center at University of Connecticut Health Center, and adjunct Professor of Chemistry at National Univ. of Ireland. Galway. Current research includes new cancer diagnostics via detection of biomarker proteins, low-cost 3D printed immunoarrays for point-of-care diagnostics, electrochemical and mass spectrometric arrays for toxicity screening, tumor suppressor gene damage, and fundamental bioelectrochemistry. He has authored more than 380 research papers and several books, and is a musician interested in Irish and American folk styles.

)

University of Connecticut
Storrs, CT
USA

R.J. Weaver (Biography
R.J. Weaver

Dr. Weaver obtained his first degree in Biochemistry & Toxicology (Hons) from the University of Surrey, Guildford, and PhD from the Dept. of Medicine & Therapeutics, University of Aberdeen. Dr. Weaver also holds a Masters of Business Administration (MBA) from the Warwick Business School, Warwick University, UK. Currently Dr Weaver is Associate Scientific Director, Servier Group, France. Affiliations included Fellow of the Royal Society of Chemistry, European Registered Toxicologist and Committee Member of the Preclinical Drug Safety and Biological Discovery Expert Committees.

)

Institut de Recherches Internationales Servier
Suresnes Cedex
France

H. Yamazaki (Biography
H. Yamazaki

Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).

)

Showa Pharma University
Tokyo
Japan



Reviewer Panel:

1. M. Gooyit (USA)
4. M. Liu (USA)
7. D. Brian (USA)
10. M. Chetty (Australia)
13. M.T. Donato (Spain)
16. D. Fuchs (Austria)
19. K. Grime (UK)
22. N. Helsby (New Zealand)
25. M. Hu (USA)
28. H. Jeong (USA)
31. R.A. Kemper (USA)
34. J. Lambert (USA)
37. F. Martel (Portugal)
40. R.P. Meyer (Germany)
43. A. Palotas (Hungary)
46. W. Tang (USA)
49. M. Vastag (Hungary)
52. Z. Yan (USA)
2. L. Berry (USA)
5. Y. Guo (USA)
8. E. Chan (Singapore)
11. B. Chowbay (Singapore)
14. Z. Dvorak (Czech Republic)
17. A. Galetin (UK)
20. J. Gu (China)
23. N. Hewitt (Germany)
26. B. Houston (UK)
29. Y. Jounaidi (USA)
32. G.M. Kirby (Canada)
35. M.-C. Liu (USA)
38. H.H. Maurer (Germany)
41. B. Moorthy (USA)
44. E. Schuetz (USA)
47. R. Tolando (Germany)
50. K. Venkatakrishnan (USA)
53. C.-H. Yun (Republic of Korea)
3. C. Guo (USA)
6. P. Anzenbacher (Czech Republic)
9. K.-C. Cheng (USA)
12. C. Collins (USA)
15. A. El-Kadi (Canada)
18. L.L. Gan (USA)
21. J. Hakkola (Finland)
24. P. Honkakoski (Finland)
27. F. Innocenti (USA)
30. A.S. Kalgutkar (USA)
33. M. Kranendonk (Portugal)
36. P.H. Marathe (USA)
39. A. McLachlan (Australia)
42. A. Nishikawa (Japan)
45. M.-R. Shiran (Iran)
48. Y.-F. Ueng (Taiwan)
51. E.L. Woodahl (USA)
54. J.Y. Zhang (China)
Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science